Hexadecanamide
Based on 1 Customer Validation
Hexadecanamide (Palmitamide) is a fatty acid amide that has orally active anti-allergic, antioxidant, and neuroprotective effects. Hexadecanamide exerts protective effects in Staphylococcus aureus- and SARA-induced mastitis. Hexadecanamide suppresses S. aureus-induced activation of the NF-κB pathway and improves blood-milk barrier integrity. Hexadecanamide activates PPARα. Hexadecanamide enhances sperm motility in vitro. Hexadecanamide can be studied in research for mastitis and asthenozoospermia.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 99.64%
- CAS 番号: 629-54-9
- 分子式: C16H33NO
- 分子量:255.44
-
保管条件:
Store at room temperature 3 years.
In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
生物活性
|
PPARα |
Hexadecanamide (Compound HEX) (5 μM, 2 h) limits the activation of mammary NF-κB via activating the PPARα-SIRT1 axis in MMECs[1].
Hexadecanamide (10 nM, 0-72 h) exerts a significant enhancing effect on sperm motility[2].
Hexadecanamide (0-1.5 nM, 72 h) results in a significant increase in the protein levels of both PAOX and CA2 in sperm cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Hexadecanamide (5 mg/kg, p.o., 10 d) effectively reduces colonic inflammation in SARA mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:S. aureus infected male and female BALB/c mice (21-25 g, 6-8 w)[1]
-
Dosage:1.25, 2.5, 5 mg/kg
-
Administration:Oral gavage (p.o.), 15 d
-
Result:Reduced inflammatory cell infiltration and structure destruction.
Decreased inflammatory markers (MPO activity, TNF-α, IL-1β) dose-dependently.
Reversed the decrease in the TJs proteins, ZO-1, Occludin, and Claudin-3 caused by S. aureus.
Repaired the blood-milk barrier injury induced by S. aureus.
-
Animal Model:BALB/c mice model with S-RMT-induced mucosal barrier injury[1]
-
Dosage:5 mg/kg
-
Administration:Oral gavage (p.o.), 10 d
-
Result:Increased mucin-2 expression and improved S-RMT-induced mucosal barrier injury in S-RMT mice.
Distinctly mitigated the upregulation of inflammatory markers caused by S-RMT.
Reversed the SARA aggravated S. aureus-induced mastitis.
化学情報
-
CAS 番号 629-54-9
-
性状 Solid
-
分子量 255.44
-
分子式 C16H33NO
-
Color White to off-white
-
SMILES
NC(CCCCCCCCCCCCCCC)=O
-
別名
Palmitamide
-
Structure Classification
-
Initial Source
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Store at room temperature 3 years
In solvent -80°C 2 years -20°C 1 year
溶剤 & 溶解度
DMSO : 5 mg/mL (19.57 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 50% PEG300 50% Saline
Solubility: 5 mg/mL (19.57 mM); Suspended solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
純度とドキュメンテーション
-
データシート (269 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. Bao L, et al. Hexadecanamide alleviates Staphylococcus aureus-induced mastitis in mice by inhibiting inflammatory responses and restoring blood-milk barrier integrity. PLoS Pathog. 2023 Nov 10;19(11):e1011764. [Content Brief]
[2]. Han B, et al. Changes in seminal plasma microecological dynamics and the mechanistic impact of core metabolite hexadecanamide in asthenozoospermia patients. Imeta. 2024 Jan 25;3(2):e166. https://pubmed.ncbi.nlm.nih.gov/38882497/ [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.9148 mL | 19.5741 mL | 39.1481 mL | 97.8703 mL |
| 5 mM | 0.7830 mL | 3.9148 mL | 7.8296 mL | 19.5741 mL | |
| 10 mM | 0.3915 mL | 1.9574 mL | 3.9148 mL | 9.7870 mL | |
| 15 mM | 0.2610 mL | 1.3049 mL | 2.6099 mL | 6.5247 mL |
Hexadecanamide 関連分類
HY-121389 関連分類
Powered by Bioz